CG Results Healthcare advises Hospira, a Pfizer company, on the divestment of its UK compounding business to Baxter

  • Service: Divestments
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech
  • Engagement Type: Sell Side
Dec 2018
Hospira, a Pfizer company, has divested its UK compounding business to

We are delighted to announce that CG Results Healthcare, part of the Results International Group, has acted as exclusive financial advisor to Pfizer on the divestment of Hospira’s UK compounding business to Baxter.

This transaction reinforces our expertise in pharmaceutical divestments.

Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, became part of Pfizer in 2015. CG Results Healthcare assisted Pfizer to focus on their strategic priorities by divesting the Hospira UK aseptic compounding business.

This transaction follows approval being granted by the Competition and Markets Authority.

Terms of the agreement were not disclosed.

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to